Incyte Corp Stock Price, News & Analysis

Incyte (Nasdaq:INCY) has appointed Soni Basi as Executive Vice President and Chief Human Resources Officer (CHRO), effective August 25, 2025. As a key member of the Executive Leadership Team, Basi will lead the company's global HR strategy, focusing on talent acquisition, organizational design, and professional development.

Basi brings over 25 years of experience in global HR and business leadership, previously serving as CHRO at Edelman where she managed 200+ HR professionals. Her prior experience includes leadership roles at AIG, Allergan Pharmaceuticals, The Estée Lauder Companies, and Schering-Plough. She succeeds Paula Swain, who has retired from her position as Executive Vice President and Head of Human Resources.

Incyte (Nasdaq:INCY) has announced its participation in three major healthcare investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference (September 3), Wells Fargo Healthcare Conference (September 4), and Morgan Stanley 23rd Annual Global Healthcare Conference (September 9).

All presentations will be accessible through live webcasts on Investor.Incyte.com and will remain available for replay for 30 days following each event.

Incyte (NASDAQ:INCY) announced that Executive Vice President and Chief Financial Officer Christiana Stamoulis will step down effective September 16, 2025, to pursue another opportunity. Stamoulis, who joined the company in 2019, will assist with the transition period while Incyte searches for her successor.

CEO Bill Meury expressed gratitude for Stamoulis's contributions and emphasized the company's focus on finding a strategic leader to execute their long-term growth plan. Importantly, Incyte reaffirmed its 2025 financial guidance previously announced on July 29, 2025, stating that its financial position and strategic direction remain unchanged.

Incyte (NASDAQ:INCY) reported strong Q2 2025 financial results with total revenues of $1.22 billion, up 16% year-over-year. Key product performance includes Jakafi revenues of $764 million (+8% Y/Y) and Opzelura revenues of $164 million (+35% Y/Y).

The company achieved significant regulatory milestones with FDA approvals for Zynyz in squamous cell anal carcinoma and Monjuvi in follicular lymphoma. Notable pipeline progress includes positive Phase 1 data for INCA033989 in essential thrombocythemia and advancement of multiple Phase 3 programs.

Incyte raised its full-year 2025 guidance for Jakafi to $3.0-3.05 billion (previously $2.95-3.0 billion) and Other Oncology to $500-520 million (previously $415-455 million). The company also announced Bill Meury as new CEO, succeeding retiring Hervé Hoppenot.

Incyte (NASDAQ:INCY) announced it will present initial data from its oncology portfolio at the ESMO Congress 2025 in Berlin, October 17-21. The presentations will feature two key developments: INCA33890, a TGFβR2×PD-1-directed bispecific antibody for advanced solid tumors, and INCB161734, a novel oral inhibitor targeting G12D-mutated KRAS.

The company will deliver an oral presentation on INCB161734's Phase 1 results on October 19, and a mini oral presentation on INCA33890's Phase 1 study on October 17. Additionally, Incyte will present data on retifanlimab combinations for head and neck cancer treatment.

Incyte (Nasdaq:INCY) has scheduled its second quarter 2025 financial results announcement for July 29, 2025. The company will release its Q2 2025 financial results via press release at 7:00 a.m. ET, followed by a conference call and webcast at 8:00 a.m. ET.

The conference call will be accessible through domestic (877-407-3042) and international (201-389-0864) dial-in numbers. A replay will be available for 30 days, and the webcast with slides will be accessible at Investor.Incyte.com for 90 days.

Incyte Corporation (Nasdaq: INCY) has announced equity inducement awards for Bill Meury, their newly appointed President and Chief Executive Officer. The compensation package includes 110,630 stock options at $70.81 per share, 36,101 restricted stock units (RSUs), and two performance share awards with target shares of 108,303 and 125,000 respectively.

The stock options have a 10-year term with 25% vesting after one year and the remainder monthly over three years. RSUs vest 25% annually over four years. The first performance share award is tied to relative TSR performance over three years, while the sign-on performance award can be earned at 0-400% of target based on stock price performance over six years.

Incyte (NASDAQ:INCY) has announced a significant leadership transition with the appointment of Bill Meury as President and CEO, effective immediately. Meury succeeds Hervé Hoppenot, who is retiring after 11 years of leading the company. Under Hoppenot's tenure, Incyte grew from a single-product U.S. company to a global enterprise, increasing revenues from $355 million in 2013 to $4.2 billion currently.

Meury brings extensive industry experience as former CEO of Karuna and Anthos Therapeutics, and previously served as Chief Commercial Officer at Allergan, where he managed a $16 billion global business. Additionally, Julian Baker has been elected Chairman of the Board of Directors. Hoppenot will remain as a board member and advisor through 2025 to ensure a smooth transition.

Incyte (INCY) announced that the FDA has extended the review period for ruxolitinib cream (Opzelura) for treating atopic dermatitis in children aged 2-11 years. The PDUFA date is pushed back by 3 months to September 19, 2025, allowing FDA to review additional CMC data for the 0.75% strength formulation. The sNDA submission was supported by Phase 3 TRuE-AD3 study results, which met its primary endpoint with significantly more patients achieving IGA-TS compared to vehicle control. The study also met its secondary endpoint with patients showing EASI75 improvement at Week 8. The safety profile remained consistent with previous data, showing only mild application site pain in 2.7% of treated patients, with no serious adverse events reported.